Showing results (941-950 of 1,984) with videos related to

Sort By:
Pageof 199
The Lancet. Neurology|July 29, 2018
Serum GFAP and UCH-L1 for prediction of absence of intracranial injuries on head CT (ALERT-TBI): a multicentre observational studyJeffrey J Bazarian, Peter Biberthaler, Robert D Welch, et al.
The Lancet. Neurology|November 22, 2005
Prevalence of movement disorders in men and women aged 50-89 years (Bruneck Study cohort): a population-based studyGregor K Wenning, Stefan Kiechl, Klaus Seppi, et al.
The Lancet. Neurology|November 22, 2005
Pathogenesis, clinical features, and neurological outcome of cerebral malariaRichard Idro, Neil E Jenkins, Charles R J C Newton
The Lancet. Neurology|December 20, 2005
The diagnosis of Parkinson's diseaseEduardo Tolosa, Gregor Wenning, Werner Poewe
The Lancet. Neurology|October 22, 2005
Single pulse electrical stimulation for identification of structural abnormalities and prediction of seizure outcome after epilepsy surgery: a prospective studyAntonio Valentín, Gonzalo Alarcón, Mrinalini Honavar, et al.
The Lancet. Neurology|October 22, 2005
The Recognition of Stroke in the Emergency Room (ROSIER) scale: development and validation of a stroke recognition instrumentAzlisham Mohd Nor, John Davis, Bas Sen, et al.
The Lancet. Neurology|October 22, 2005
Low-grade gliomas: an update on pathology and therapyRobert Cavaliere, Maria Beatriz S Lopes, David Schiff
The Lancet. Neurology|August 22, 2018
Selective autophagy as a potential therapeutic target for neurodegenerative disordersAurora Scrivo, Mathieu Bourdenx, Olatz Pampliega, et al.
The Lancet. Neurology|February 6, 2010
Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trialIvo N van Schaik, Filip Eftimov, Pieter A van Doorn, et al.
The Lancet. Neurology|May 3, 2017
Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trialStewart Tepper, Messoud Ashina, Uwe Reuter, et al.
Pageof 199